— Why it moved
Why TVRD Stock Nearly Doubled Today — July 7, 2026
Phase 1 data for a next-gen STAT3 inhibitor hit a 5.7M-share float, and the move round-tripped by lunch.
What moved it
Tvardi put out Phase 1 results for TTI-109, the follow-up to its STAT3 inhibitor TTI-101. Cleaner tolerability, dose-proportional pharmacokinetics, some target-engagement markers. Real news, but it's a healthy-volunteer study, and the release says taking it further depends on regulatory clearance and funding. Funding is the word to notice at this market cap.
The mechanics
Float is 5.7M shares on a ~$19M cap. About 70M shares traded, so the float turned over roughly 12 times. That structure turns any decent headline into a vertical candle. This is a momentum move, not a re-rating.
Numbers
- Cap: ~$19M / float: 5.7M
- Volume: ~70M (~245x the 30-day avg)
- Prev close: $2.01 → closed $3.10 (+54%)
- Short interest: ~7% of float
- 52w range: $1.50–$43.65
Where it ended up
Stock Pulse flagged it at 10:59 ET at $3.27, already up 60%+ on the session. The top was $3.86 at 11:13, fourteen minutes later. It bled to $2.75 by early afternoon and finished at $3.10, under the alert print.
Reality check
- Peak to close was a 20% fade. Anyone who bought after 11:15 ended the day red.
- The lead drug failed Phase 2 in IPF last October, which is where the $43 in that 52w range comes from. The latest 10-Q carries going-concern language, so dilution is the base case.
- This already happened. It's a breakdown of why it ran, not a reason to buy it.